뒤로
Better Therapeutics Inc (BTTX) 수입
BTTX 주가 차트
BTTX 수입
Better Therapeutics Inc
$0
0%
$0
종가: Apr 02, 16:00:00 GMT-4
$0
0%
$0
애프터마켓: Apr 02, 20:00:00 GMT-4
최신 수익 결과: Q3 '23
보고됨: 2023-11-09
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
BTTX의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Better Therapeutics Inc BTTX의 지난 분기 매출 실적은 어땠나요?
Better Therapeutics Inc의 매출 추정치는 얼마인가요?
Better Therapeutics Inc의 수익 품질 점수는 얼마인가요?
Better Therapeutics Inc는 언제 수익을 보고하나요?
Better Therapeutics Inc의 예상 수익은 얼마인가요?
Better Therapeutics Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0.0001
시가
$0.0001
일일 범위
$0.0001 - $0.0001
52주 범위
$0.0001 - $0.001
거래량
500
평균 거래량
2.7K
배당수익률
--
EPS(TTM)
-1.16
시가총액
$4.9K
BTTX란 무엇인가요?
Better Therapeutics, Inc. operates as a digital therapeutics company, which engages in developing a novel form of cognitive behavioral therapy to address the root causes of cardio metabolic diseases. The company is headquartered in San Francisco, California and currently employs 54 full-time employees. The company went IPO on 2021-01-08. Its platform allows for the creation of multiple PDTs that are designed to treat patients with CBT, delivered digitally via an app, to address the underlying causes of CMDx. Its lead PDT product candidate, AspyreRx, is a digital behavioral therapeutic delivering CBT for the treatment of a cardiometabolic disease. AspyreRx is a prescription-only digital treatment indicated to provide cognitive behavioral therapy to patients 18 years or older with T2D. The device targets behavior to aid in the treatment of T2D. Its pipeline also includes programs for the treatment of hypertension, hyperlipidemia, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metabolic Dysfunction-Associated Steatohepatitis (MASH) and chronic kidney disease.